World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
86
Citations
43703
World Ranking
13866
National Ranking
47

Do-Youn Oh publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Do-Youn Oh sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 767 publications — 85th percentile

85% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Do-Youn Oh D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Do-Youn Oh sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Do-Youn Oh is affiliated with Seoul National University in South Korea and has contributed extensively to the field of medicine, particularly oncology. Their research spans multiple subfields, including pulmonary and respiratory medicine, surgery, molecular biology, and radiology, nuclear medicine, and imaging.

The scientist's work focuses prominently on cancer-related topics. Main areas of study include cholangiocarcinoma and gallbladder cancer, gastric cancer management and outcomes, pancreatic and hepatic oncology, cancer immunotherapy and biomarkers, colorectal cancer treatments, peptidase inhibition and analysis, and gastrointestinal tumor research and treatment.

Selected recent publications authored or co-authored by Do-Youn Oh include:

  • Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer, 2022, NEJM Evidence
  • Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study, 2020, The Lancet Oncology
  • Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study, 2020, The Lancet Oncology
  • Biliary tract cancer, 2021, The Lancet
  • Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial, 2022, The Lancet Oncology

Frequent co-authors in their work include:

  • Sun Young Rha
  • Teresa Macarulla
  • Jeesun Yoon
  • Jin Won Kim
  • Joon Oh Park

Do-Youn Oh has published in several notable scientific venues, with a significant number of works appearing in:

  • Journal of Clinical Oncology
  • Cancer Research
  • Annals of Oncology
  • The Lancet Oncology
  • Cancer Research and Treatment

Their research output highlights a sustained engagement with multiple dimensions of oncology and medical research, contributing to advancements in treatments and clinical understanding of various cancer types.

Best Publications

  • Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

    Sunil Verma;David Miles;Luca Gianni;Ian E. Krop

  • Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    Yoon Koo Kang;Narikazu Boku;Taroh Satoh;Min Hee Ryu

  • Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

    Talia Golan;Pascal Hammel;Michele Reni;Eric Van Cutsem

  • Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

    Ghassan K. Abou-Alfa;Ghassan K. Abou-Alfa;Vaibhav Sahai;Antoine Hollebecque;Gina Vaccaro

  • Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

    James C. Yao;Nicola Fazio;Simron Singh;Roberto Buzzoni

  • Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

    Sae-Won Han;Tae-You Kim;Pil Gyu Hwang;Soohyun Jeong

  • HER2-targeted therapies — a role beyond breast cancer

    Do Youn Oh;Yung Jue Bang

  • Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

    Ghassan K. Abou-Alfa;Ghassan K. Abou-Alfa;Teresa Macarulla;Milind M. Javle;Robin K. Kelley

  • Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

    Milind Javle;Maeve Lowery;Rachna T. Shroff;Karl Heinz Weiss

  • Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.

    Jin Young Jang;Youngmin Han;Hongeun Lee;Sun Whe Kim

  • Biliary tract cancer

    Juan W. Valle;Juan W. Valle;R. Katie Kelley;Bruno Nervi;Do Youn Oh

  • Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.

    Eileen M. O'Reilly;Do Youn Oh;Neesha Dhani;Daniel J. Renouf

  • A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

    Jeffrey R. Infante;Bradley G. Somer;Joon Oh Park;Chung-Pin Li;Chung-Pin Li

  • Efficacy and Safety of Pembrolizumab for the Treatment of Advanced Biliary Cancer: Results From the KEYNOTE-158 and KEYNOTE-028 Studies

    Sarina A. Piha-Paul;Do Youn Oh;Makoto Ueno;David Malka

  • Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.

    Andrew X. Zhu;Teresa Macarulla;Milind M. Javle;R. Kate Kelley

  • Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.

    Bhumsuk Keam;Seock-Ah Im;Kyung-Hun Lee;Sae-Won Han

  • Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.

    Younak Choi;Do-Youn Oh;Tae-Yong Kim;Kyung-Hun Lee

  • First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors

    Yung-Jue Bang;G. Giaccone;S. A. Im;D. Y. Oh

  • A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data

    Li Tzong Chen;Taroh Satoh;Min Hee Ryu;Yee Chao

  • Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.

    Bhumsuk Keam;Seock-Ah Im;Hee-Jun Kim;Do-Youn Oh

Frequent Co-Authors

Seock-Ah Im
Seock-Ah Im Seoul National University Hospital
Yung-Jue Bang
Yung-Jue Bang Seoul National University
Dong-Wan Kim
Dong-Wan Kim Seoul National University Hospital
Dong-Young Noh
Dong-Young Noh Seoul National University
Dae Seog Heo
Dae Seog Heo Seoul National University Hospital
Se-Hoon Lee
Se-Hoon Lee Sungkyunkwan University
Woo Kyung Moon
Woo Kyung Moon Seoul National University Hospital
Woo Ho Kim
Woo Ho Kim Seoul National University
Jae-Gahb Park
Jae-Gahb Park National Cancer Center
Yoon Kyung Jeon
Yoon Kyung Jeon Seoul National University Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternatives to traditional medical degrees can open up a variety of rewarding healthcare careers. For students interested in management and leadership roles, pursuing a health administration degree online is an excellent option. This pathway offers accelerated learning and the flexibility to study from anywhere.

Registered nurses aiming to advance their qualifications can enroll in asn to np bridge programs. These programs prepare nurses to become nurse practitioners, enabling them to provide a higher level of patient care and often command higher salaries.

If your interest lies in diet and wellness, some of the best online nutrition programs can help launch a career in nutrition counseling, community outreach, or research—all in a flexible, online format.

Finally, those seeking advanced roles in healthcare management might consider enrolling in one of the top cahme-accredited mha programs. Accreditation ensures high-quality education and is valued by employers nationwide.

Best Scientists Citing Do-Youn Oh

Trending Scientists

Recently Published Articles